LUMAKRAS® (SOTORASIB) CODEBREAK 100 STUDY SHOWS TWO-YEAR OVERALL SURVIVAL OF 32.5% IN PATIENTS WITH KRAS G12C-MUTATED ADVANCED NON-SMALL CELL LUNG CANCER

Long-Term Clinical Benefit and Prolonged Tumor Response Seen With 40.7% Objective Response Rate No New Safety Signals Observed Longest Follow-Up of Patients Treated With a KRASG12C Inhibitor THOUSAND OAKS, Calif., April 10, 2022 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced the...

Click to view original post